title: [Diagnosis and treatment of incidental prostate cancer following TUPVP (a report of 15 cases)].
abstract: OBJECTIVE
  To investigate the diagnosis and treatment of incidental prostate cancer (IPC) following transurethral plasma kinetic vaporization prostatectomy (TUPVP).
  
  
  METHODS
  Pathological examinations were conducted on 134 benign prostate hyperplasia specimens by means of series microtomy after TUPVP.
  
  
  RESULTS
  Fifteen cases of IPC were detected from the total number of TUPVP specimens, with a pick-up rate of 11.2%. Dual testicle resection with endocrine therapy was performed in 4 cases of Stage A2 patients, and endocrine therapy alone was conducted in 9 cases of Stage A1 patients. Thirteen patients were followed up for 7 to 15 months and all lived without cancer (PSA 0.15 - 4.0 microg/L).
  
  
  CONCLUSIONS
  TUPVP and series microtomy may be helpful to the diagnosis of IPC. Patients at Stage A1 need mere endocrine therapy, while those at Stage A2 warrant dual testicle resection.
authors.affiliation: Department of Urology, Affiliated Hospital of Nanjing TCM University, Nanjing, Jiangsu 210029, China.
authors.forename: Xiaojian
authors.initials: X
authors.lastname: Gu
authors.forename: Qingyi
authors.initials: Q
authors.lastname: Zhu
authors.forename: Ping
authors.initials: P
authors.lastname: Zhang
authors.forename: Yada
authors.initials: Y
authors.lastname: Zhang
authors.forename: Zijie
authors.initials: Z
authors.lastname: Lu
authors.forename: Yan
authors.initials: Y
authors.lastname: Xu
authors.forename: Shugang
authors.initials: S
authors.lastname: Huang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009919:Orchiectomy; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000473:pathology* / Q000601:surgery; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000601:surgery*; D020728:Transurethral Resection of Prostate
chemical_list: D017430:Prostate-Specific Antigen